QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 barclays-maintains-overweight-on-solid-biosciences-lowers-price-target-to-15

Barclays analyst Gena Wang maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and lowers the price target from $18 ...

 hc-wainwright--co-reiterates-buy-on-solid-biosciences-maintains-16-price-target

HC Wainwright & Co. analyst Arthur He reiterates Solid Biosciences (NASDAQ:SLDB) with a Buy and maintains $16 price target.

 solid-biosciences-q2-eps-061-beats-067-estimate

Solid Biosciences (NASDAQ:SLDB) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $(0...

 jp-morgan-upgrades-solid-biosciences-to-overweight-raises-price-target-to-15

JP Morgan analyst Anupam Rama upgrades Solid Biosciences (NASDAQ:SLDB) from Neutral to Overweight and raises the price targe...

 leerink-partners-upgrades-solid-biosciences-to-outperform-maintains-price-target-to-12

Leerink Partners analyst Joseph Schwartz upgrades Solid Biosciences (NASDAQ:SLDB) from Market Perform to Outperform and main...

 piper-sandler-reiterates-overweight-on-solid-biosciences-maintains-20-price-target

Piper Sandler analyst Biren Amin reiterates Solid Biosciences (NASDAQ:SLDB) with a Overweight and maintains $20 price target.

 jp-morgan-maintains-neutral-on-solid-biosciences-lowers-price-target-to-10

JP Morgan analyst Anupam Rama maintains Solid Biosciences (NASDAQ:SLDB) with a Neutral and lowers the price target from $12 ...

 hc-wainwright--co-reiterates-buy-on-solid-biosciences-maintains-16-price-target

HC Wainwright & Co. analyst Arthur He reiterates Solid Biosciences (NASDAQ:SLDB) with a Buy and maintains $16 price target.

 barclays-maintains-overweight-on-solid-biosciences-lowers-price-target-to-18

Barclays analyst Gena Wang maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and lowers the price target from $21 ...

 solid-biosciences-q1-eps-064-inline

Solid Biosciences (NASDAQ:SLDB) reported quarterly losses of $(0.64) per share which met the analyst consensus estimate. This i...

 solid-biosciences-receives-rare-pediatric-disease-designation-from-the-fda-for-duchenne-muscular-dystrophy-gene-therapy-candidate-sgt-003

Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for neuromuscular and card...

 william-blair-initiates-coverage-on-solid-biosciences-with-outperform-rating-announces-price-target-of-40

William Blair analyst Tim Lugo initiates coverage on Solid Biosciences (NASDAQ:SLDB) with a Outperform rating and announces ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION